All Stories

Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M

In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic rhinosinusitis (CRS) nasal spray Xhance for up to $330 million.

Mar 20, 2025 - 16:26
 0
Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic rhinosinusitis (CRS) nasal spray Xhance for up to $330 million.
Read More

Tags:

Previous Article

Mitsubishi Motors: Xforce HEV model premieres in Thailand

Next Article

Human medicines European public assessment report (EPAR): Constella, linaclotide...

Related Posts

Pfizer enlists Elizabeth Banks for Gen X-focused pneumococcal vaccine push

Pfizer enlists Elizabeth Banks for Gen X-focused pneumo...

Mar 19, 2025  0

Amid Vafseo's US launch, Akebia plots phase 3 study to grow CKD anemia med's reach

Amid Vafseo's US launch, Akebia plots phase 3 study to ...

Mar 13, 2025  0

Sarepta reports one death after patient received DMD gene therapy Elevidys

Sarepta reports one death after patient received DMD ge...

Mar 19, 2025  0